Home / Articles / 9 Biomarkers That Indicate Poor Gut Health? Evidence-Based Answer Without the Hype

Evidence-based response

9 Biomarkers That Indicate Poor Gut Health? Evidence-Based Answer Without the Hype

Gut biomarkers can be useful when the clinical question is specific. Fecal calprotectin is established, but many microbiome, permeability, and metabolite markers are still context-dependent.

By Sandra McKenzy, Pharmacist · 2026-05-31

Whiteboard split between evidence cards and an overclaim bubble around gut biomarkers - biomarkers indicating poor gut health
Gut biomarkers can support a clinical question, but no single marker proves poor gut health by itself.

Short answer: Some gut biomarkers are useful, but the phrase “poor gut health” is not a diagnosis. Fecal calprotectin can help flag intestinal inflammation. Stool microbiome diversity, short-chain fatty acids, permeability markers, secretory IgA, and dysbiosis scores can generate hypotheses, but they need symptoms, medication history, diet, repeatability, and clinician interpretation before they should guide medical decisions.

What are gut health biomarkers?

Gut health biomarkers are measurable signals from stool, blood, breath, or urine that may reflect inflammation, transit, infection, fermentation, barrier function, immune activity, or microbial composition. The important word is may. A biomarker is only as useful as the question it answers.

A marker such as fecal calprotectin is clinically established because it tracks neutrophil-driven intestinal inflammation and can help distinguish inflammatory bowel disease from functional symptoms in the right pathway. A broad microbiome diversity score is different. It can describe a stool sample, but it usually cannot tell a person why they are bloated, tired, anxious, constipated, or reacting to foods.

Evidence summary

Evidence summary
  • Fecal calprotectin is one of the more clinically useful stool markers for intestinal inflammation.
  • Microbiome composition varies by geography, diet, drugs, sampling method, and reference database.
  • Low diversity or altered taxa can be associated with disease, but association is not diagnosis.
  • SCFAs and butyrate are biologically important, yet stool levels are difficult to turn into simple personal prescriptions.
  • Permeability and zonulin-style markers remain more uncertain than many wellness reports imply.
  • Persistent symptoms or red flags need medical evaluation, not only a consumer biomarker panel.

Which biomarkers are most clinically useful?

Fecal calprotectin is the clearest example. It is not perfect and it does not name the disease by itself, but elevated values can support further evaluation for inflammatory bowel disease, infection, medication injury, or other inflammatory conditions. Fecal lactoferrin and other inflammatory stool proteins can point in a similar direction, although local clinical pathways differ.

FIT, stool pathogen testing, ova and parasite testing, pancreatic elastase, fecal fat testing, and calprotectin are useful because they answer narrower medical questions. They are not general wellness scores. They are chosen because the clinician is asking: is there blood, inflammation, infection, malabsorption, or another defined problem?

Can microbiome diversity show poor gut health?

Low microbial diversity is often discussed as a warning sign. In population research, diversity can correlate with diet, medication exposure, disease states, and resilience. But a single person's diversity score does not automatically prove disease or identify a treatment. Reference ranges are limited by geography, diet, age, sequencing method, and the comparison group used by the laboratory.

This matters because two reports can describe the same sample differently. DNA extraction kits, stool handling, database choice, and whether the lab uses 16S or shotgun metagenomics can change what is reported. A diversity score should be read as context, not as a verdict.

What about SCFAs, butyrate, and metabolite markers?

Short-chain fatty acids such as acetate, propionate, and butyrate are central to colon biology. They are produced when microbes ferment fibers and resistant starches. Butyrate supports epithelial energy metabolism and has immune effects. That does not mean a low stool butyrate result proves one cause or one supplement answer.

Stool metabolite values reflect diet, transit time, sampling conditions, microbial activity, absorption, and host physiology. They can be useful in research and may sometimes help clinical thinking, but the safest first-line advice remains boring for a reason: enough fiber, diverse plants, fewer ultra-processed foods, appropriate medical care for persistent symptoms, and no extreme protocols based on one number.

Are zonulin and permeability tests reliable?

Intestinal barrier biology is real. The gut lining controls what crosses from the lumen into the body, and barrier disruption is relevant in several diseases. The problem is translation into consumer testing. Some commercial zonulin-family assays have interpretation problems, and a result often does not map cleanly onto a diagnosis or treatment plan.

Lactulose-mannitol testing and other permeability methods can be informative in research or selected clinical contexts, but they are affected by protocol, timing, kidney handling, transit, and disease context. Treat “leaky gut score” claims cautiously unless the lab explains what was measured, how it was validated, and what clinical action follows.

What marketing gets wrong about nine-biomarker panels

The common overreach is bundling established clinical markers with emerging or weakly validated markers, then presenting the whole panel as a personalized map of poor gut health. That can make the report feel more certain than the science allows. A list of nine numbers is not automatically better than one well-chosen test.

Another mistake is linking nonspecific symptoms directly to a biomarker pattern. Bloating, fatigue, food intolerance, skin flares, and brain fog can have many causes. A microbiome profile may suggest a hypothesis, but anemia, thyroid disease, celiac disease, inflammatory bowel disease, infection, medication effects, sleep problems, and stress physiology may be more relevant in a given person.

When should biomarkers prompt a clinician visit?

Ask a clinician before relying on a wellness panel if you have blood in stool, black stools, persistent diarrhea, fever, unexplained weight loss, anemia, severe abdominal pain, nighttime symptoms, recurrent vomiting, dehydration, recent antibiotics with watery diarrhea, immune suppression, inflammatory bowel disease, or a family history of colorectal cancer.

Also seek medical help if a test reports very high inflammatory markers, possible pathogens, or severe malabsorption. Those findings need confirmation and clinical context. Do not try to suppress them with supplements before the cause is understood.

Bottom line

Gut biomarkers can reduce guesswork when they are chosen for a specific question. They become misleading when they are treated as a universal health dashboard. Fecal calprotectin and other clinical stool tests can be valuable. Consumer microbiome and permeability markers can be educational, but they should stay in the category of hypotheses unless validated against the person, the symptom pattern, and the clinical pathway.

Evidence notes

  • Mizuno et al. (2017). Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?. Nature Reviews Gastroenterology & Hepatology. 10.1038/nrgastro.2017.29
  • He et al. (2018). Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nature Medicine. 10.1038/s41591-018-0164-x
  • Costea et al. (2019). Stool sampling and DNA isolation kits affect DNA quality and bacterial composition following 16S rRNA gene sequencing. Scientific Reports. 10.1038/s41598-019-49520-3
  • Lee et al. (2024). Validation of rapid fecal calprotectin assay using particle enhanced turbidimetric immunoassay for inflammatory bowel disease. Scientific Reports. 10.1038/s41598-024-51580-z
  • Wilkinson et al. (2022). Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders. Nature Reviews Gastroenterology & Hepatology. 10.1038/s41575-022-00581-2
  • Noecker et al. (2024). Microbial community-scale metabolic modelling predicts personalized short-chain fatty acid production profiles in the human gut. Nature Microbiology. 10.1038/s41564-024-01728-4
  • Pearce et al. (2023). Ex vivo intestinal permeability assay for tracking barrier function dynamics. npj Biofilms and Microbiomes. 10.1038/s41522-023-00409-0

This article is educational and does not diagnose, treat, or replace care from a qualified clinician.